KPV Protocol Guide: The Complete Physician-Supervised Approach to Anti-Inflammatory & Gut Health
KPV is a tripeptide fragment (Lys-Pro-Val) derived from alpha-melanocyte-stimulating hormone (alpha-MSH) that possesses potent anti-inflammatory properties without the melanogenic (skin-darkening) effects of full-length alpha-MSH. It is one of the most promising peptides for gut inflammation, IBD support, and systemic inflammatory conditions.
Protocol Quick Reference
Who Is This Protocol For?
KPV is suited for individuals dealing with chronic inflammation, particularly in the gastrointestinal tract or skin. Its selective anti-inflammatory action makes it a targeted tool for conditions driven by NF-kB pathway overactivation. Common candidates include:
- Individuals with inflammatory bowel disease (IBD) including ulcerative colitis and Crohn's disease seeking adjunctive peptide support
- Those with chronic gut inflammation such as leaky gut, IBS with inflammatory markers, or post-infectious gut dysfunction
- People with inflammatory skin conditions including eczema, dermatitis, psoriasis, or chronic inflammatory acne
- Individuals with systemic inflammation reflected in elevated hs-CRP, ESR, or inflammatory cytokine levels
- Those seeking a targeted anti-inflammatory that works through specific NF-kB modulation rather than broad immunosuppression
KPV is not recommended for pregnant or breastfeeding women, individuals with known hypersensitivity to alpha-MSH derivatives, or those with active infections requiring immune activation (KPV dampens inflammatory response). Your Hatter Labs physician will review inflammatory markers and clinical history before prescribing.
How KPV Works: Mechanism of Action
KPV is the C-terminal tripeptide of alpha-MSH (amino acids 11-13). While full-length alpha-MSH activates melanocortin receptors (causing skin darkening and other systemic effects), KPV retains the anti-inflammatory activity through a distinct mechanism that does not require melanocortin receptor activation.
Primary Mechanisms
- NF-kB pathway inhibition: KPV directly inhibits nuclear factor kappa-B (NF-kB) — the master transcription factor for inflammatory gene expression. By preventing NF-kB translocation to the nucleus, KPV suppresses the production of pro-inflammatory cytokines including TNF-alpha, IL-1beta, IL-6, and IL-8.
- Intestinal epithelial cell penetration: Uniquely, KPV can enter intestinal epithelial cells and exert anti-inflammatory effects directly within the gut wall. Research shows it can be delivered orally in nanoparticle formulations and maintain efficacy in the gut lumen.
- T-cell modulation: KPV suppresses the activation and proliferation of inflammatory T-cell subsets in the gut mucosa, reducing the immune-mediated tissue damage characteristic of IBD.
- Antimicrobial peptide regulation: KPV modulates the production of antimicrobial peptides by epithelial cells, helping to maintain the gut barrier against pathogenic bacteria while reducing inflammatory overreaction.
- Skin inflammation reduction: In dermal cells, KPV reduces keratinocyte inflammatory signaling, decreases mast cell degranulation, and inhibits the inflammatory cascades driving eczema, psoriasis, and contact dermatitis.
Clinical Note: A landmark 2019 study in Cellular and Molecular Gastroenterology and Hepatology demonstrated that orally delivered KPV-loaded nanoparticles significantly reduced colitis severity in animal models, with direct anti-inflammatory action in the colonic epithelium. Human clinical trials for IBD applications are in development. The ability to deliver KPV orally makes it uniquely accessible compared to most peptides.
Detailed Protocol
KPV is one of the few peptides that can be administered both by injection and orally (in capsule form), depending on the target condition. Gut-focused protocols often use oral delivery.
| Parameter | Gut Health Protocol | Systemic/Skin Protocol |
|---|---|---|
| Daily Dosage | 200-500 mcg/day oral | 200-500 mcg/day subcutaneous |
| Frequency | Once or twice daily | Once daily |
| Administration | Oral capsule (fasted preferred) | Subcutaneous injection |
| Injection Site | N/A (oral) | Abdominal fat pad or near affected area |
| Duration | 4-8 weeks | 4-6 weeks |
| Time of Day | Morning fasted + evening before bed | Morning |
| Cycling | 4-8 weeks on, 2-4 weeks off | 4-6 weeks on, 2-4 weeks off |
Personalization Note: Hatter Labs physicians check inflammatory markers (hs-CRP, ESR, calprotectin for gut protocols) before and during KPV therapy. For IBD patients, coordination with your gastroenterologist ensures KPV complements your existing treatment rather than replacing it.
What to Expect: Results Timeline
Week 1-2: Initial Anti-Inflammatory Phase
- - Reduction in gut symptoms: less bloating, reduced cramping, more regular bowel movements
- - Decreased skin redness and irritation for inflammatory skin conditions
- - Subtle improvement in overall comfort and reduced background inflammation
- - Some individuals notice improved energy as inflammatory burden decreases
Week 3-4: Active Healing Phase
- - Significant reduction in IBD symptoms for gut-focused protocols
- - Measurable decrease in inflammatory markers (CRP, calprotectin trending down)
- - Skin conditions showing visible improvement — less flaking, redness, irritation
- - Improved food tolerance and reduced food sensitivities
- - Enhanced gut barrier function reducing systemic inflammatory load
Week 5-8+: Consolidation Phase
- - Sustained remission or significant improvement in inflammatory symptoms
- - Normalized inflammatory markers on repeat bloodwork
- - Skin conditions in remission or markedly improved
- - Improved quality of life and reduced dependence on anti-inflammatory medications
- - Your physician evaluates whether to continue, cycle off, or move to maintenance
KPV results are enhanced by dietary modifications (anti-inflammatory diet, elimination of trigger foods), stress management, and addressing underlying gut microbiome imbalances. Your Hatter Labs physician may coordinate with a nutritionist for comprehensive gut health protocols.
Potential Side Effects
KPV has a favorable safety profile. As a small tripeptide fragment, it lacks the melanogenic and hormonal effects of full-length alpha-MSH. It does not cause skin darkening, appetite changes, or sexual side effects.
Common (mild, usually transient)
- Mild gastrointestinal discomfort when starting oral protocols (usually resolves within days)
- Injection site redness or minor irritation (for subcutaneous protocols)
- Mild headache during the first few days
- Temporary changes in bowel habits as gut inflammation resolves
Uncommon (report to your physician)
- Persistent GI symptoms that worsen rather than improve
- New or worsening skin reactions
- Signs of immune suppression (increased susceptibility to infections)
- Allergic reaction (rash, swelling, difficulty breathing) — seek immediate medical attention
Safety Note: Because KPV suppresses NF-kB signaling, it may temporarily reduce inflammatory immune responses needed to fight active infections. If you develop an infection while on KPV therapy, contact your Hatter Labs physician to discuss temporary protocol suspension.
Stacking Options
KPV combines effectively with other gut-healing and immune-modulating peptides for comprehensive inflammatory condition management.
KPV + BPC-157
The definitive gut healing stack. KPV addresses the inflammatory component (NF-kB suppression) while BPC-157 drives tissue repair through angiogenesis, growth factor modulation, and mucosal barrier restoration. Together they reduce inflammation and rebuild damaged gut tissue simultaneously.
KPV + LL-37
Anti-inflammatory plus antimicrobial defense. KPV calms the inflammatory cascade while LL-37 addresses bacterial biofilms and pathogenic overgrowth that may be driving the inflammation. This stack is particularly useful when gut inflammation coexists with dysbiosis or chronic infection.
KPV + BPC-157 + LL-37 (Complete Gut Restoration Stack)
The most comprehensive approach to gut health restoration. Anti-inflammatory action (KPV), tissue repair and barrier restoration (BPC-157), and antimicrobial defense (LL-37). This stack addresses all three pillars of gut dysfunction: inflammation, tissue damage, and microbial imbalance.
Why Run Your KPV Protocol with Hatter Labs
Inflammatory conditions require precise management — the right amount of immune modulation without over-suppression. Hatter Labs provides the clinical oversight and lab monitoring to ensure your KPV protocol is effective and safe.
Physician-Supervised Protocols
Licensed physicians design and monitor your protocol from start to finish
Personalized Dosing Based on Labs
CRP, calprotectin, ESR, and immune panels guide your protocol
Direct Doctor Chat & Remote Consultations
Message your physician anytime with questions or concerns, schedule video calls
Before & After Lab Testing
Track inflammatory markers, gut health biomarkers, and immune function objectively
Pharmaceutical-Grade Compounds
Premium peptides sourced from licensed US compounding pharmacies with full purity testing
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. KPV is a research peptide that requires a physician prescription. Individual results vary. Always consult with a qualified healthcare provider before starting any peptide therapy protocol. Hatter Labs protocols are supervised by licensed physicians who evaluate your health history, contraindications, and treatment goals before prescribing.